What Teligent, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Yachmetz Philip K | EVP, Chief Legal Off, Corp Sec | Jul 16 | Withheld — tax / exercise cost · F | −2,656 | $0.47 | −$1.25K | 5,179 |
| Yachmetz Philip K | EVP, Chief Legal Off, Corp Sec | Jul 16 | Exercise / conversion · M | +7,835 | — | — | 7,835 |
| Pate R Carter | Director | May 27 | Open-market buy · P | +30,000 | $0.55 | +$16.5K | 30,000 |
| Life Sciences Opportunities Fund Instittutional Ii Lp | Director | Aug 26 | Open-market sale · S | −85,106 | $1.25 | −$106K | 17,515 |
| Life Sciences Opportunities Fund Instittutional Ii Lp | Director | Aug 26 | Open-market sale · S | −475,512 | $1.24 | −$591K | 98,390 |
| Life Sciences Opportunities Fund Instittutional Ii Lp | Director | Aug 25 | Open-market sale · S | −15,184 | $1.13 | −$17.1K | 102,621 |
| Life Sciences Opportunities Fund Instittutional Ii Lp | Director | Aug 25 | Open-market sale · S | −84,816 | $1.13 | −$96.1K | 573,902 |
| Life Sciences Opportunities Fund Instittutional Ii Lp | Director | Aug 21 | Open-market sale · S | −18,432 | $1.66 | −$30.5K | 117,805 |
| Life Sciences Opportunities Fund Instittutional Ii Lp | Director | Aug 21 | Open-market sale · S | −102,962 | $1.66 | −$171K | 658,718 |
| Life Sciences Opportunities Fund Instittutional Ii Lp | Director | Aug 19 | Open-market sale · S | −13,251 | $2.25 | −$29.8K | 136,237 |
| Life Sciences Opportunities Fund Instittutional Ii Lp | Director | Aug 19 | Open-market sale · S | −74,020 | $2.26 | −$167K | 761,680 |
| Chaudhuri Bhaskar | Director | Jun 03 | Open-market buy · P | +10,000 | $0.70 | +$7.01K | 10,000 |
| Sabatino Thomas J Jr | Director | May 31 | Open-market buy · P | +25,000 | $0.66 | +$16.5K | 25,000 |
| Celentano John E | Director | May 31 | Open-market buy · P | +20,000 | $0.65 | +$12.9K | 20,000 |
| Gale James C | Director | May 31 | Open-market buy · P | +20,000 | $0.66 | +$13.2K | 394,624 |
| Ben-maimon Carole | Director | May 30 | Open-market buy · P | +10,000 | $0.59 | +$5.89K | 16,000 |
| Grenfell-Gardner Jason | President & CEO | May 23 | Open-market buy · P | +25,000 | $0.69 | +$17.3K | 119,849 |
| Gale James C | Director | May 23 | Open-market buy · P | +20,000 | $0.69 | +$13.8K | 374,624 |
| Finio Damian | CFO | Dec 14 | Open-market buy · P | +10,000 | $1.82 | +$18.2K | 10,000 |
| Richardson Stephen | Chief Scientific Officer | Dec 14 | Open-market buy · P | +12,000 | $1.78 | +$21.4K | 51,209 |
Loading...
